Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder

Mithramycin (MTR) is a clinically approved DNA-binding antitumor antibiotic currently in Phase 2 clinical trials at National Institutes of Health for treatment of osteosarcoma. In view of the resurgence in the studies of this generic antibiotic as a human medicine, we have examined the binding prope...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Amrita, Sanyal, Sulagna, Kulkarni, Kirti K., Jana, Kuladip, Roy, Siddhartha, Das, Chandrima, Dasgupta, Dipak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247356/
https://www.ncbi.nlm.nih.gov/pubmed/25473595
http://dx.doi.org/10.1016/j.fob.2014.10.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247356/
https://www.ncbi.nlm.nih.gov/pubmed/25473595
http://dx.doi.org/10.1016/j.fob.2014.10.007

Ejemplares similares